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Abstract: Many men with erectile dysfunction (ED) also have associated underlying 
cardiovascular and metabolic conditions, for which they are likely to be taking medication. 
Therefore, cardiovascular safety and potential drug interactions are two of the major concerns 
when using PDE-5 inhibitors in these patients. The PDE-5 inhibitor, vardenafil, is characterized 
by a rapid onset of action, increased duration of erection, high rates of first-dose success and 
reliable efficacy that can be maintained with continued use. In both clinical trials and real-life 
observational studies, vardenafil has demonstrated a favorable efficacy and safety profile in men 
with ED, including those with associated underlying conditions such as diabetes, hypertension 
and dyslipidemia. Importantly, the concomitant use of medication for these conditions is not 
associated with any noteworthy changes in the efficacy and safety of vardenafil. The evidence 
presented in this review supports the use of vardenafil as a first-line treatment for men with ED, 
including those with underlying conditions.
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Introduction
Erectile dysfunction (ED) is a common condition affecting an estimated 150 million 
men worldwide.1,2 ED is frequently associated with loss of self esteem and can 
impact significantly on the quality of life and well being of both members of a 
couple.3–6 Organic ED and cardiovascular disease share the same risk factors, including 
diabetes, hypertension, dyslipidemia, obesity and smoking.7,8 These two conditions 
also share the same pathophysiology, with endothelial dysfunction, inflammatory 
and endothelial-prothrombotic activation, and oxidative stress being their common 
denominators.9,10 It is increasingly being recognized by researchers that ED may be 
considered a predictor for the development of cardiovascular disease.11–13 Biennial 
screening of a random sample of community-dwelling men (n = 1402) over a 10-year 
period revealed that the presence of ED was associated with an approximately 80% 
higher risk of subsequent coronary artery disease (CAD).14 A study conducted in men 
with type 2 diabetes who had silent CAD (n = 291) found that patients who experienced 
major adverse cardiac events over a follow-up period of approximately 4 years were 
significantly more likely to have ED than those who did not (61% vs 36%, respectively; 
P  0.001).15 There is evidence that in patients with established CAD, ED symptoms 
appeared an average of 2 to 5 years earlier than those of CAD itself.16,17 A diagnosis of 
ED therefore provides a golden opportunity for clinicians to assess men’s cardiovascular 
health, and intervene at an early stage in the disease pathway.Clinical Interventions in Aging 2009:4 464
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The introduction in the late 1990s of highly effective oral 
pharmacotherapies for ED transformed ED management and 
led to an increase in the number of men seeking treatment.18 
Nevertheless, the rate of ED sufferers seeking medical help is 
still low,19,20 despite the dramatic impact on overall quality of life 
and the potential as an indicator for cardiovascular prevention. 
Current guidelines recommend the phosphodiesterase type 5 
(PDE-5) inhibitors, vardenafil, sildenafil and tadalafil, as first-
line therapy for ED of varying etiologies and severity.21,22 
Vardenafil is a selective PDE-5 inhibitor, with a profile 
characterized by rapid onset of action, increased duration of 
erection, high rates of first-dose success and reliable efficacy 
that can be maintained with continued use.23–31
This review examines the epidemiology of ED, in 
particular, in men with associated underlying conditions, 
and evaluates the evidence compiled on the clinical efficacy 
and safety of vardenafil.
Epidemiological evidence 
demonstrating the association 
between ED and underlying 
conditions
Large-scale epidemiological studies have found the prevalence 
of ED in the general population of men aged 18 to 64 years 
to be 10% to 16%.20,32 The prevalence and severity of 
ED increases with age.18,33–35 In the Epidemiologia de la 
Disfuncion Erectil Masculina (EDEM) study, ED prevalence 
rates were 3.9% in the 25- to 39-year age group, rising to 
32.3% in those men aged 50 to 70 years.34 The Massachu-
setts Male Aging Study (MMAS) found that between the 
age of 40 and 70 years, the probability of having complete 
ED increased 3-fold from 5% to 15%, with a corresponding 
2-fold increase from 17% to 34% in the probability of  having 
moderate ED.18
Numerous studies have explored the close association 
between ED and cardiovascular disease. Evidence shows that 
cardiovascular risk factors (CRFs) are present in the majority 
of men with ED, while men with ED are more likely to have 
CRFs than those with no ED.20,36,37 A high prevalence of ED 
has been reported in patients with CAD, with rates ranging 
from 44% to 75%.38,39 In men with diabetes, ED prevalence 
rates can vary between 35% and 90%.40–42 A prospective 
cohort study of men over 50 years of age (n = 31,027) found 
the prevalence of ED in men with diabetes to be almost double 
that in men without diabetes (46% vs 24%, respectively). 
ED in men with diabetes is also frequently more severe, 
compared with the general ED population.43
Research has demonstrated a considerable difference 
in hypertension prevalence rates between patients with and 
without ED (41% vs 19%, respectively).37 A correlation 
has also been observed between increasing hypertension 
prevalence and increased ED severity.44 Studies have 
documented the association between ED and serum lipid 
levels. An analysis of a nationally representative man-
aged care claims database in the United States found the 
prevalence rate of hyperlipidemia to be 42% among men 
with ED.45 In a study of 215 men with ED and 100 men 
without ED, the prevalence of hypercholesterolemia (total 
cholesterol 200 mg/dL or 5.17 mmol/L) was 71% vs 52%, 
respectively (P = 0.06). Both high-density lipoprotein (HDL) 
cholesterol and total cholesterol/HDL cholesterol ratios were 
shown to be significant predictors of ED (P = 0.011 and 
P  0.0001, respectively).46
The Massachusetts Male Aging Study, a community-
based, random sample of men aged 40 to 70 years, found an 
inverse correlation between age-adjusted probability of ED 
and levels of HDL cholesterol.18 In men aged 40 to 55 years, 
the age-adjusted probability of having moderate ED increased 
from 7% to 25% with a decrease in HDL cholesterol levels 
from 90 mg/dL (2.3 mmol/L) to 30 mg/dL (0.9 mmol/L). 
Similarly, other studies have found correlations between 
ED and both decreased HDL cholesterol and elevated total 
cholesterol/HDL cholesterol ratio.47,48
The cluster of cardiovascular and metabolic risk factors 
that are often described as the “metabolic syndrome” 
include increased abdominal obesity, elevated triglycerides, 
reduced HDL cholesterol, hypertension, increased fasting 
plasma glucose and hyperinsulinemia.49–52 There is a close 
association between metabolic syndrome, and both ED 
and hypogonadism.53,54 In a study of 1086 men with ED, 
the prevalence of metabolic syndrome was 32% using 
the National Cholesterol Education Program-Third Adult 
Treatment Panel (NCEP-ATP III) definition, and 45% using 
the International Diabetes Federation definition.50
Testosterone regulates the formation of cyclic guanosine 
monophosphate (cGMP), through its effect on nitric oxide 
synthase expression, and on cGMP catabolism, through 
its effect on PDE-5 isoenzyme expression. Hypogonadism 
is believed to play a major role in the pathophysiology 
of ED, with a minimum threshold testosterone level 
required for normal erectile function.55 Prevalence rates of 
hypogonadism in men with ED range from 2% to 35%.56,57 
The close association between testosterone deficiency, ED 
and underlying conditions may contribute to a decline in 
men’s overall health, if left untreated.52Clinical Interventions in Aging 2009:4 465
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Efficacy of vardenafil in men with ED
Clinical efficacy
Diabetes
The trend towards the onset of diabetes at a younger age 
within the general population, combined with a higher 
prevalence of childhood type 2 diabetes, is expected to 
lead to an increase in men developing diabetes-related 
ED.58 Management of ED in patients with diabetes can be 
challenging, since ED is often more severe and resistant to 
long-term treatment in this patient group.43,59 Furthermore, 
worsening glycemic control is associated with greater 
impairment of erectile function.60
Favorable efficacy of vardenafil in men with diabetes has 
been demonstrated in a number of clinical trials.  A double-blind, 
placebo-controlled trial in men with type 1 or type 2 
diabetes (n = 452) demonstrated significant improvements 
in the erectile function domain of the International Index of 
Erectile Function (IIEF-EF) scores and Sexual Encounter 
Profile question 2 (SEP2: “Were you able to insert your 
penis into your partner’s vagina?”) and 3 (SEP3: “Did your 
erection last long enough for you to have successful inter-
course?”) success rates following 12 weeks of treatment 
with 10 mg or 20 mg vardenafil compared with placebo 
(all P  0.0001). After 12 weeks, changes from baseline 
in IIEF-EF scores were 5.9 and 7.8 for 10 mg and 20 mg 
vardenafil, respectively, compared with 1.4 for placebo 
(P  0.0001).61 No relationship between response to 
vardenafil and level of glycemic control (defined as level 
of glycosylated hemoglobin [HbA1c]) was observed. For 
men with ED and good-to-moderate (HbA1c  6 but  8%; 
n = 64) or poor (HbA1c  8%; n = 71) glycemic control, 
SEP3 success rates were 50% and 54%, respectively, in 
those taking 20 mg vardenafil, compared with 20% (n = 56) 
and 23% (n = 77) for placebo-treated men. SEP3 responses 
were significantly superior to placebo for both 10 mg and 
20 mg vardenafil in all glycemic control subgroups.
Similar findings were reported in a randomized, 
double-blind, placebo-controlled trial in Japan in men with 
diabetes (defined as levels of HbA1c  6.5% or receiving 
hypoglycemic drug treatment).62 IIEF-EF scores improved 
significantly from 13.6 and 13.9 at baseline to 21.8 and 22.9 
at last observation carried forward (LOCF) in the 10 mg and 
20 mg vardenafil groups, respectively, compared with an 
increase from 13.7 to 16.3 for placebo (P  0.0001).
Hypertension
The number of patients with hypertension has risen 
considerably in recent years.63 Accordingly, given the 
close association between ED and hypertension, the need 
to determine the efficacy and safety of PDE-5 inhibitors 
for ED therapy in this patient group has assumed greater 
importance. A 12-week, multicenter, randomized, double-
blind, placebo-controlled trial conducted in Germany 
investigated the efficacy of flexible-dose vardenafil in men 
with ED and arterial hypertension, which was adequately 
controlled with at least one antihypertensive medication.64 
Compared with placebo, vardenafil significantly improved 
SEP2 and SEP3 success rates over the study period 
(P  0.0001). In vardenafil-treated patients, average SEP2 
success rates increased from 50% at baseline to 84% at 
week 12, compared with a corresponding increase from 49% 
to 59% in the placebo group. SEP3 rates increased from 
18% at baseline to 68% at week 12 in the vardenafil group, 
compared with an increase from 18% to 35% for placebo. 
Improved erections (measured by the Global Assessment 
Question: “Has the treatment you have taken over the past 
4 weeks improved your erections?”) were reported by 80% 
of patients receiving vardenafil versus 40% of those on 
placebo.
Shabsigh et al conducted a meta-analysis of 8 randomized, 
double-blind, placebo-controlled, flexible-dose trials of 
vardenafil in men with ED (n = 2427), where 839 patients 
(35%) had self-reported hypertension.44 After 12 weeks of 
vardenafil treatment, statistically significant and clinically 
meaningful improvements were observed in all primary 
outcome measures (IIEF-EF, SEP2, SEP3), compared 
with placebo. IIEF-EF scores increased by an average of 
8.9 points, while SEP2 and SEP3 success rates increased by 
an average of 32.4% and 38.0%, respectively. A comparison 
of men with and without hypertension showed no significant 
differences in any of the three outcome measures, suggesting 
that vardenafil is equally efficacious for the treatment of ED 
in both patient groups.
Dyslipidemia
Dyslipidemia is believed to be a causal factor in the endothelial 
damage thought to underlie many cases of organic ED.59 It has 
been demonstrated that statin therapy to correct lipid levels 
improves penile rigidity in men with ED and hypercholes-
terolemia.65 There are few studies evaluating the efficacy 
of PDE-5 inhibitors in men with ED and dyslipidemia. 
A 12-week, double-blind, placebo-controlled study inves-
tigated the efficacy of flexible-dose vardenafil in men with 
ED and dyslipidemia on stable statin therapy.28 In addition to 
dyslipidemia, 61% of subjects had hypertension and 40% had 
diabetes. Vardenafil treatment was associated with significant Clinical Interventions in Aging 2009:4 466
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improvements in IIEF-EF scores and SEP2 and SEP3 success 
rates compared with placebo (P  0.001). After 12 weeks 
of treatment, least squares (LS) mean IIEF-EF scores using 
LOCF were 22.0 vs 14.8 for vardenafil vs placebo, while LS 
adjusted mean success rates for vardenafil vs placebo were: 
SEP2, 79.1% vs 51.9% and SEP3, 66.7% vs 33.8%.
Efficacy of vardenafil in patients with ED taking 
concomitant medications
A recent pooled analysis was conducted on individual patient 
data from 13 randomized, double-blind, placebo-controlled 
trials of flexible-dose vardenafil of at least 12 weeks’ duration.66 
Primary efficacy measures were the IIEF-EF, SEP2 and SEP3. 
Efficacy was assessed in subgroups of patients with ED and 
co-existing diabetes, hypertension and dyslipidemia according 
to type of concomitant medication taken. Consistent with the 
findings of earlier studies, the concomitant use of medications 
was not associated with any noteworthy changes in the efficacy 
of vardenafil. Across all subgroups, vardenafil was statistically 
superior to placebo over 12 weeks of treatment (P  0.0001) 
(Figures 1 to 6). Further, vardenafil treatment resulted in a 
significant improvement from baseline in IIEF-EF scores 
and SEP2 and SEP3 success rates, irrespective of the type 
of medication used (P  0.0001) (Figures 1 to 6).
Efficacy of vardenafil in aging men
Vardenafil improves erectile function in men with ED, 
including patients over the age of 65 years, the age group 
in which ED is most prevalent.67 A 12-week multicenter, 
randomized, double-blind, placebo-controlled, at-home study 
of vardenafil 5, 10 and 20 mg was conducted in men (n = 580) 
with mild to severe ED. In a subgroup analysis in which 
patients were split into 4 age groups (45 years, 45 to 55 
years, 56 to 65 years and 65 years), mean IIEF-EF scores 
across all age groups were significantly greater for vardenafil-
treated patients than those treated with placebo (P  0.001). 
No significant differences in the efficacy of vardenafil were 
observed between age groups.
Duration of erection: a new clinical efficacy measure 
for vardenafil
Improving penile hardness in men with ED is commonly 
believed to be the most important factor contributing to 
successful sexual intercourse. However, there is a body of 
evidence suggesting that duration of erection, and hence duration 
of intercourse, may play a role in achieving a satisfactory 
sexual experience for the man and his partner.68,69
Recent clinical data have demonstrated that vardenafil 
significantly improves duration of erection in men with ED, 
including those with underlying conditions. In these stud-
ies, a novel efficacy parameter, stopwatch-assessed dura-
tion of erection, was employed. A randomized, multicenter, 
double-blind, placebo-controlled crossover study of 
fixed-dose vardenafil was conducted in a broad population 
of men with ED, which included patients with diabetes, 
hypertension, hyperlipidemia and hypercholesterolemia.29 
Placebo
Men with ED and diabetes
No drugs used
n =
460
524
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214
188
223
28
42
45
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LS mean IIEF-EF score at week 12 LOCF
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+ other drugs
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**
Figure 1 LS mean IIEF-EF scores in patients with ED and diabetes, stratified by type of antidiabetic medication, at baseline and following 12 weeks of treatment with vardenafil 
or placebo. Reproduced with permission from Eardley I, Lee Jay C, Shabsigh R, et al.    Vardenafil improves erectile function in men with erectile dysfunction and associated 
underlying conditions, irrespective of the use of concomitant medications.   J Sex Med. 2009.66 In press. Copyright © 2009    Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.1972 for comparison of antidiabetic medication subgroups.
Abbreviations: ED, erectile dysfunction; IIEF-EF, erectile function domain of the International Index of Erectile Function; LOCF, last observation carried forward; LS, least squares.Clinical Interventions in Aging 2009:4 467
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Over 4 weeks of treatment, vardenafil produced a ~2.3-fold 
longer duration of erection than placebo (P  0.001). 
Vardenafil also demonstrated a statistically significant 
superiority over placebo in IIEF-EF scores and SEP2 and 
SEP3 success rates (all P  0.001). Duration of erection was 
also a secondary outcome measure in the study of vardenafil 
in men with ED and dyslipidemia on stable statin therapy 
discussed earlier.28 In this study, vardenafil treatment was 
associated with a ~3.0-fold longer duration of erection, 
compared with placebo (P  0.001).
Placebo
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Figure 2 LS mean SEP3 success rates in patients with ED and diabetes, stratified by type of antidiabetic medication, at baseline and following 12 weeks of treatment with 
vardenafil or placebo. Reproduced with permission from Eardley I, Lee  Jay C, Shabsigh R, et al.   Vardenafil improves erectile function in men with erectile dysfunction and 
associated underlying conditions, irrespective of the use of concomitant medications.  J Sex Med. 2009.66 In press. Copyright © 2009   Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.0986 for comparison of antidiabetic medication subgroups.
Abbreviations: ED, erectile dysfunction; LOCF, last observation carried forward; LS, least squares; SEP, sexual encounter profile question.
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Figure 3 LS mean IIEF-EF scores in patients with ED and hypertension, stratified by type of antihypertensive medication, at baseline and following 12 weeks of treatment 
with vardenafil or placebo. Reproduced with permission from Eardley I, Lee  Jay C, Shabsigh R, et al.   Vardenafil improves erectile function in men with erectile dysfunction and 
associated underlying conditions, irrespective of the use of concomitant medications.  J Sex Med. 2009.66 In press. Copyright © 2009   Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.1651 for comparison of antihypertensive medication subgroups.
Abbreviations: ACE, angiotensin-converting enzyme;   ARB, angiotensin II receptor antagonists; B, beta blockers; C, calcium channel antagonists; D, thiazide or thiazide-like 
diuretics; ED, erectile dysfunction; IIEF-EF, erectile function domain of the International Index of Erectile Function; LOCF, last observation carried forward; LS, least squares.Clinical Interventions in Aging 2009:4 468
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Figure 4 LS mean SEP3 success rates in patients with ED and hypertension, stratified by type of antihypertensive medication, at baseline and following 12 weeks of treatment 
with vardenafil or placebo. Reproduced with permission from Eardley I, Lee  Jay C, Shabsigh R, et al.   Vardenafil improves erectile function in men with erectile dysfunction 
and associated underlying conditions, irrespective of the use of concomitant medications.  J Sex Med. 2009.66 In press. Copyright © 2009   Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.7957 for comparison of antihypertensive medication subgroups.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor antagonists; B, beta blockers; C, calcium channel antagonists; D, thiazide or thiazide-like 
diuretics; ED, erectile dysfunction; LOCF, last observation carried forward; LS, least squares; SEP, sexual encounter profile question.
Efficacy of vardenafil in a real-life 
observational study
Numerous controlled clinical trials have demonstrated the 
efficacy of vardenafil in men with ED, including those 
with associated underlying conditions. These findings were 
also confirmed in a large observational, open-label study 
of vardenafil involving over 100,000 participants world-
wide.70,71 The Real-Life Safety and Efficacy of vardenafil 
(REALISE) study recruited patients presenting to their 
physician with ED and involved a follow-up period of 
Placebo Vardenafil Baseline
n =
Men with ED and dyslipidemia
Statins monotherapy 
Statins + other drugs 
LS mean IIEF-EF score at week 12 LOCF
Other drugs
484
559
358
427
64
71
57
56
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12.2
19.7*
20.7* **
21.6*
21.2*
0 5 10 15 20 25
Figure 5 LS mean IIEF-EF scores in patients with ED and dyslipidemia, stratified by type of lipid-lowering medication, at baseline and following 12 weeks of treatment 
with vardenafil or placebo. Reproduced with permission from Eardley I, Lee  Jay C, Shabsigh R, et al.   Vardenafil improves erectile function in men with erectile dysfunction 
and associated underlying conditions, irrespective of the use of concomitant medications.  J Sex Med. 2009.66 In press. Copyright © 2009   Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.9169 for comparison of lipid-lowering medication subgroups.
Abbreviations: ED, erectile dysfunction; IIEF-EF, erectile function domain of the International Index of Erectile Function; LOCF, last observation carried forward; LS, least squares.Clinical Interventions in Aging 2009:4 469
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2 months. An initially prescribed dose of vardenafil could be 
titrated within the observation period, according to physician 
recommendation and labeling instructions. Most patients 
were prescribed vardenafil 10 mg as a starting dose. Treat-
ment outcome was assessed by physician interview; in addi-
tion, a voluntary patient questionnaire was used to assess each 
attempt at sexual intercourse. Although data from REALISE 
are uncontrolled, they represent real-world experiences with 
vardenafil, in contrast to rigidly controlled clinical trials.
A pooled analysis of REALISE data from 47 countries in 
Europe, Asia-Pacific, Latin America and the rest of the world 
(excluding the United States) has recently been performed (van 
Ahlen et al in preparation). Data were stratified by the presence 
of diabetes, hypertension or lipid metabolism disorder. In all 
subgroups, high numbers of patients reported improvements in 
erectile function (diabetes, 92.6%; hypertension, 93.6%; lipid 
metabolism disorder, 94.7%). A large proportion of patients 
also reported being ‘satisfied’ or ‘very satisfied’ with the 
efficacy of vardenafil (hypertension 92.0%; diabetes 90.9%; 
lipid metabolism disorder 93.4%), and stated their intention to 
continue vardenafil use after the end of the study period.
Safety and tolerability of vardenafil 
in men with ED and underlying 
conditions
Interactions between food/alcohol  
and vardenafil
Vardenafil is rapidly absorbed after the administration of 
a single oral dose. Absorption is unaffected when taken in 
conjunction with a meal containing a moderate amount of 
fat; however, very high fat meals (ie, meals in which more 
than 57% of the calories come from fat) can affect the 
rate, but not the extent, of absorption.72 The simultaneous 
administration of vardenafil and alcohol does not result in 
any clinically relevant pharmacokinetic or pharmacodynamic 
interactions.73
Adverse events
The side-effect profile of vardenafil is typical of PDE-5 inhib-
itors. Commonly reported adverse events in patients receiving 
vardenafil include headache, rhinitis, flushing and dyspep-
sia.74,75 Most men with concomitant cardiovascular disease, 
including heart failure and stable arrhythmias, can be safely 
treated for ED with vardenafil or other PDE-5 inhibitors.76 
Eardley et al’s previously described analysis,66 conducted 
upon data from a large pool of patients with ED and underly-
ing conditions, showed that the use of concomitant medica-
tions did not affect the safety or tolerability of vardenafil in 
patients with diabetes, hypertension or dyslipidemia. The 
number and type of the most frequent treatment-emergent 
adverse events were comparable with those of other studies 
of PDE-5 inhibitors in these patient groups.
Contraindications
Like other PDE-5 inhibitors, vardenafil is contraindicated in 
patients taking organic nitrates (eg, nitroglycerin, isosorbide 
mono- or dinitrate), nitrate preparations used to treat angina, 
amyl nitrate or amyl nitrite.21,77 This is thought to be due to 
a stimulation of soluble guanylate cyclase by nitric oxide, 
n =
455 
474
334 
352
64 
68
52 
50
22.4
29.3
28.6
26.9
LS mean SEP3 success rate at week 12 LOCF (%)
Men with ED and dyslipidemia
Statins monotherapy 
Statins + other drugs 
Other drugs
58.1*
61.4*
** 55.3*
47.7*
Placebo Vardenafil Baseline
0 10         20 30         40 60 70 50
Figure 6 LS mean SEP3 success rates in patients with ED and dyslipidemia, stratified by type of lipid-lowering medication, at baseline and following 12 weeks of treatment 
with vardenafil or placebo. Reproduced with permission from Eardley I, Lee  Jay C, Shabsigh R, et al.   Vardenafil improves erectile function in men with erectile dysfunction 
and associated underlying conditions, irrespective of the use of concomitant medications.  J Sex Med. 2009.66 In press. Copyright © 2009   Wiley-Blackwell.
*P  0.0001 for vardenafil vs placebo, **P = 0.3536 for comparison of lipid-lowering medication subgroups.
Abbreviations: ED, erectile dysfunction; LOCF, last observation carried forward; LS, least squares; SEP, sexual encounter profile question.Clinical Interventions in Aging 2009:4 470
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resulting in a large cGMP accumulation which in turn and 
through a cascade of events leads to smooth muscle relaxation, 
and thus to a decrease in blood pressure. In patients taking 
alpha blockers (for the treatment of hypertension and/or 
benign prostatic hyperplasia), vardenafil should be used with 
caution and patients’ blood pressure carefully monitored. 
Caution is also recommended with the use of vardenafil 
in the presence of cytochrome P450, family 3, subfamily 
A (CYP3A) inhibitors, such as azole antifungal agents, 
antiretroviral protease inhibitors, macrolid antibiotics, or 
grapefruit juice.78
Expert opinion
The introduction onto the market of the first PDE-5 
inhibitor more than a decade ago profoundly revolutionized 
medical perceptions of ED, and opened the way to oral 
pharmacological therapy for this condition. For a long time, 
experts had denied that there was an underlying organic 
cause of ED, and almost invariably, patients suffering from 
ED were referred for counselling to address psychological 
issues. Improvements in our knowledge and understanding 
of erectile function were triggered in the late 1980s, with the 
introduction of intracavernosal injections of vasoactive drugs, 
followed by therapy with oral agents to safely and effectively 
treat ED. Risk factors for ED and associated underlying 
conditions have now been identified, and it is widely 
accepted that a man presenting with ED in the physician’s 
office warrants a thorough evaluation of his metabolic 
and cardiovascular status, in addition to a comprehensive 
psycho-social-sexual history.
PDE-5 inhibitors constitute the first-line treatment option 
for men affected by ED, to be combined with counseling on 
lifestyle, diet, exercise and weight control, if required. A major 
concern when using PDE-5 inhibitors in men presenting with 
ED and associated underlying conditions has been cardiovas-
cular safety and potential drug interactions. Apart from the well 
established absolute contraindication of concomitant use with 
nitrates or nitric oxide donors, PDE-5 inhibitors have demon-
strated excellent safety and efficacy profiles over time.
The data provided in this review demonstrate the efficacy, 
safety, effectiveness and satisfaction of vardenafil in two 
different sample populations: men presenting with ED and 
associated underlying conditions enrolled in clinical trials, 
and men presenting with ED without contraindications for 
vardenafil use, enrolled in a large observational study. Efficacy 
data are derived from clinical trials, effectiveness and satisfac-
tion data are derived from real-life scenarios, and safety data 
are derived from all the studies reviewed. Physicians should 
be confident about safety when prescribing vardenafil to 
patients with ED and associated underlying conditions. Men 
with underlying conditions are more likely to suffer from 
ED, which is generally of greater severity. Taking into con-
sideration overall efficacy, patients’ responses to vardenafil 
treatment are significantly superior compared with placebo, 
regardless of underlying clinical condition or outcome mea-
sure/instrument used (ie, the conventional SEP2, SEP3 and 
IIEF parameters, or the newly proposed duration of erection 
measure). This response is also consistent with data obtained 
from real-life situations, where a high patient satisfaction rate 
was also demonstrated. Together, this evidence supports the 
use of vardenafil as a first-line efficacious treatment option for 
men presenting with ED and underlying conditions.
Conclusion
In light of the evidence that many men with ED also 
have associated underlying cardiovascular and metabolic 
conditions, it is important to evaluate the efficacy and safety 
of PDE-5 inhibitors for ED therapy in these patient groups. 
There is a significant body of evidence demonstrating the 
favorable efficacy and safety profile of vardenafil in men with 
ED and associated underlying conditions including diabetes, 
hypertension and dyslipidemia. Importantly, the concomitant 
use of medications, including antihypertensive agents, is not 
associated with any decreases in efficacy or safety.
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